Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00580385 · ClinicalTrials.gov registry record · NA

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

A NA study of Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
763
Enrollment target
1
Study location

NCT00580385 is a NA study of Osteosarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 763 participants, above the 285-participant average among 46 other Osteosarcoma trials with a reported enrollment target (168% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00580385, a NA study of Osteosarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
763 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.

Conditions Studied

Interventions

  • OTHER Tissue Procurement

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 763 participants
Start Date 1997-08
Est. Completion 2026-08
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00580385

The ClinicalTrials.gov registry entry for NCT00580385 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 763 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 285-participant average among 46 other Osteosarcoma trials with a reported enrollment target (168% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Tissue Procurement is the first listed.

NCT00580385 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00580385 about?

NCT00580385 is a clinical study titled "Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors". The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samp...

What is the current status of trial NCT00580385?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 763 participants. The study started on 1997-08. Estimated completion is 2026-08.

What conditions does trial NCT00580385 study?

This clinical trial studies the following conditions: Osteosarcoma.

What interventions are being tested in trial NCT00580385?

The interventions under investigation include: Tissue Procurement (OTHER).

Who is sponsoring clinical trial NCT00580385?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00580385 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteosarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.